See more : Yangtzekiang Garment Limited (0294.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Brii Biosciences Limited (2137.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Brii Biosciences Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Shenwan Hongyuan (H.K.) Limited (0218.HK) Income Statement Analysis – Financial Results
- Reconnaissance Energy Africa Ltd. (RECO.V) Income Statement Analysis – Financial Results
- Kairous Acquisition Corp. Limited (KACL) Income Statement Analysis – Financial Results
- Shantou Wanshun New Material Group Co., Ltd. (300057.SZ) Income Statement Analysis – Financial Results
- Zamil Industrial Investment Company (2240.SR) Income Statement Analysis – Financial Results
Brii Biosciences Limited (2137.HK)
About Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 56.32M | 51.63M | 92.54M | 82.22M | 20.20M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 56.32M | 51.63M | 92.54M | 82.22M | 20.20M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 402.71M | 440.63M | 494.62M | 875.80M | 83.79M |
| General & Administrative | 55.69M | 53.47M | 79.31M | 49.84M | 22.55M |
| Selling & Marketing | 1.42M | 26.86M | 0.00 | 0.00 | 0.00 |
| SG&A | 57.10M | 80.33M | 79.31M | 49.84M | 22.55M |
| Other Expenses | -459.19M | 44.85M | 68.69M | -13.75M | 20.59M |
| Operating Expenses | 617.00K | 565.81M | 642.61M | 911.88M | 126.92M |
| Cost & Expenses | 600.62M | 565.81M | 642.61M | 911.88M | 126.92M |
| Interest Income | 108.02M | 37.20M | 6.49M | 2.41M | 143.00K |
| Interest Expense | 494.00K | 851.00K | 1.18M | 1.67M | 1.11M |
| Depreciation & Amortization | 15.67M | 17.03M | 7.68M | 6.19M | 2.81M |
| EBITDA | -168.20M | -503.58M | -602.80M | -890.79M | -124.11M |
| EBITDA Ratio | -298.64% | -975.45% | -4,557.33% | -1,523.53% | -2,563.48% |
| Operating Income | -544.30M | -520.62M | -4.23B | -1.27B | -525.21M |
| Operating Income Ratio | -966.41% | -1,008.44% | -4,575.98% | -1,540.81% | -2,600.58% |
| Total Other Income/Expenses | 359.93M | 24.41M | -3.58B | -386.54M | -394.11M |
| Income Before Tax | -184.37M | -489.78M | -4.19B | -1.28B | -521.03M |
| Income Before Tax Ratio | -327.35% | -948.71% | -4,528.85% | -1,561.11% | -2,579.86% |
| Income Tax Expense | 0.00 | -37.16M | -70.86M | -77.22M | -4.19M |
| Net Income | -174.83M | -452.63M | -4.12B | -1.21B | -516.84M |
| Net Income Ratio | -310.41% | -876.74% | -4,452.28% | -1,467.18% | -2,559.14% |
| EPS | -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| EPS Diluted | -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| Weighted Avg Shares Out | 728.10M | 723.48M | 439.05M | 706.20M | 706.20M |
| Weighted Avg Shares Out (Dil) | 728.10M | 723.48M | 439.05M | 706.20M | 706.20M |
Source: https://incomestatements.info
Category: Stock Reports